Publications by authors named "Dimitris Voliotis"

Claim this Profile
E
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Jordi Bruix, Jean-Luc Raoul, Morris Sherman, Vincenzo Mazzaferro, Luigi Bolondi, Dimitris Voliotis

J Hepatol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
Ann-Lii Cheng, Zhongzhen Guan, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Dimitris Voliotis

Eur J Cancer· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
Jean-Luc Raoul, Jordi Bruix, Tim F Greten, Morris Sherman, Vincenzo Mazzaferro, Dimitris Voliotis

J Hepatol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.
Ghassan K Abou-Alfa, Dino Amadori, Armando Santoro, Arie Figer, Jacques De Greve, Dimitris Voliotis

Gastrointest Cancer Res· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Dimitris Voliotis

Lancet Oncol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Dimitris Voliotis

N Engl J Med· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Richard A Larson, Eric L Sievers, Edward A Stadtmauer, Bob Löwenberg, Elihu H Estey, Dimitris Voliotis

Cancer· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Dirk Strumberg, Heike Richly, Ralf A Hilger, Norbert Schleucher, Sonke Korfee, Dimitris Voliotis

J Clin Oncol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
Martina Heim, Mariam Scharifi, Jochen Zisowsky, Ulrich Jaehde, Dimitris Voliotis

Anticancer Drugs· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in treating hematologic malignancies.
Dimitris Voliotis, Volker Diehl

Semin Oncol· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.
Beate Gleissner, Nicola Gökbuget, Claus R Bartram, Bart Janssen, Harald Rieder, Dimitris Voliotis

Blood· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis